Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

Humana and ChenMed Announce Five-Year Network Agreement: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana and ChenMed Announce Five-Year Network Agreement


ChenMed, one of the largest senior-focused primary care providers in the United States, and leading health and well-being company Humana Inc. (NYSE: HUM) have signed a new five-year agreement

Humana Healthy Horizons to Support Maternal Health of Black Moms in Kentucky via Programs, Grants: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Healthy Horizons to Support Maternal Health of Black Moms in Kentucky via Programs, Grants


Humana Healthy Horizons in Kentucky, Humana’s (NYSE: HUM) Kentucky Medicaid Plan, is pleased to announce that three local community-based organizations will receive grants totaling $120,000 from

PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCEhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
PFIZER REPORTS RECORD FULL-YEAR 2022 RESULTS AND PROVIDES FULL-YEAR 2023 FINANCIAL GUIDANCE


Pfizer Inc. (NYSE: PFE) reported exceptional financial results for fourth-quarter and full-year 2022 and provided 2023 financial guidance(4).



The fourth-quarter 2022 earnings presentation and

Agilent to Announce First-Quarter Fiscal Year 2023 Financial Results Feb. 28:
Agilent to Announce First-Quarter Fiscal Year 2023 Financial Results Feb. 28


Agilent Technologies Inc. (NYSE: A) will release financial results for the first quarter of fiscal year 2023 after the stock market closes on Tuesday, Feb. 28. The company will host a live webcast

Go365 by Humana Announces Winners of Fifth Annual National Step Challenge, Resulting in 7.1 Billion Steps Taken and One Million Meals* Donated to Feeding America®: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Go365 by Humana Announces Winners of Fifth Annual National Step Challenge, Resulting in 7.1 Billion Steps Taken and One Million Meals* Donated to Feeding America®


Today, leading health and well-being company, Humana Inc. (NYSE: HUM), announced the winners** of its 2022 Go365® National Step Challenge – a health and wellness competition that focuses on

Karen Moran Named President of Humana Military: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Karen Moran Named President of Humana Military


Humana Military, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), announced today that it has appointed healthcare industry veteran Karen Moran to Senior Vice President, President of Humana

Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Schedules Fourth Quarter and Full Year 2022 Earnings Release and Conference Call for February 9, 2023 at 4:30 p.m. Eastern Time


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and full year 2022 financial results after market close on Thursday, February 9, 2023. Management will hold a

Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test: https://unsplash.com/photos/MJX7-BAdkt0
Agilent to Collaborate with Quest Diagnostics to Extend Access to the Agilent Resolution ctDx FIRST Liquid Biopsy Test


Agilent Technologies Inc. (NYSE: A) today announced an agreement with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services. The alliance will enable

CenterWell Senior Primary Care Expands Personalized Primary Care to Charlotte, Opening 3 New Centers in 2023: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
CenterWell Senior Primary Care Expands Personalized Primary Care to Charlotte, Opening 3 New Centers in 2023


CenterWell Senior Primary Care will open three new senior-focused primary care centers in Charlotte this year, marking the company’s debut in the city and giving seniors access to CenterWell’s

Agilent Included in Just Capital’s 2023 List of Most Just Companies: https://unsplash.com/photos/26h317_UMYM
Agilent Included in Just Capital’s 2023 List of Most Just Companies


Agilent Technologies Inc. (NYSE: A) is ranked 35 among the top 100 Most JUST companies, the fifth year the company has been included in the annual list by Just Capital and CNBC. Agilent also earned

Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countrieshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries


Pfizer Inc. (NYSE: PFE) today announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has

Humana, Feeding America® Partner to Support Mobile Food Pantries: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana, Feeding America® Partner to Support Mobile Food Pantries


Leading health and wellness company Humana Inc. (NYSE: HUM) is helping to address food insecurity with a $625,000 grant to Feeding America, supporting mobile food pantries in nine states.


This

Agilent Authorizes $2 Billion Share Repurchase Program: https://www.flatex.at/fileadmin/dateien_flatex/images/logos/logo-claim_flatex-at_positiv_rgb.png
Agilent Authorizes $2 Billion Share Repurchase Program


Agilent Technologies Inc. (NYSE: A) today announced that its board of directors has approved a new share repurchase program. The 2023 program authorizes the purchase of up to $2 billion of the

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2022 and Initial 2023 Outlook


DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31

Dexcom Appoints Teri Lawver as Chief Commercial Officer: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Appoints Teri Lawver as Chief Commercial Officer


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the appointment of Teri Lawver to the newly created role of chief

QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho Reports Preliminary Revenue Results for Fourth Quarter and Full Year 2022


QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and

Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications:
Agilent and Akoya Biosciences Announce Partnership to Drive Multiplex Tissue Assay Development for Biopharma Applications


Agilent Technologies, Inc. (NYSE: A) today announced a partnership with Akoya Biosciences, Inc. (Nasdaq: AKYA), The Spatial Biology Company®, to develop multiplex-immunohistochemistry diagnostic

U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Childrenhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children


Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for priority review a supplemental Biologics License Application (sBLA) for its 20-valent

Waters Corporation Recognized for its Award-winning Products, Outstanding Leadership, and ESG Progress: https://mms.businesswire.com/media/20191105005256/en/560437/5/Waters_logo_K.jpg
Waters Corporation Recognized for its Award-winning Products, Outstanding Leadership, and ESG Progress


Waters Corporation (NYSE:WAT) announced awards and recognitions from multiple independent industry organizations throughout 2022, highlighting strength and momentum of the company’s product

Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research:
Agilent Announces Acquisition of Avida Biomed, Developer of High-Performance NGS Target Enrichment Workflows for Cancer Research


Agilent Technologies Inc. (NYSE: A) today announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conferencehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 41st Annual J.P. Morgan

Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom to Present at 41st Annual J.P. Morgan Healthcare Conference


DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 41st annual J.P. Morgan Healthcare

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidatehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Announces Positive Top-Line Results from Phase 3 Study of Hemophilia B Gene Therapy Candidate


Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the

QuidelOrtho to Present at the J.P. Morgan Healthcare Conference: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho to Present at the J.P. Morgan Healthcare Conference


QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion

U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescentshttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
U.S. FDA Accepts for Review the Biologics License Application for Pfizer’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents


Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for review a Biologics License Application (BLA) for its investigational pentavalent meningococcal